ContractClinical Trial Agreement • November 11th, 2016
Contract Type FiledNovember 11th, 2016CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-296-1080 SMLOUVA O KLINICKÉ STUDII PRO PROTOKOL GS-US-296-1080 This Clinical Trial Agreement (“Agreement”) is entered into as of 08 November 2016 (the “Effective Date”) by and amongUniversity Hospital Olomouc, located at I.P.Pavlova 185/6, 779 00 Olomouc, Czech Republic, Company ID (IČ): 00098892, Tax ID no.: CZ00098892, represented by doc. MUDr. Roman Havlík, Ph.D. (hereinafter the “Institution”) AND Gilead Sciences, Inc., a Delaware corporation with headquarters located at 333 Lakeside Drive, Foster City, California, 94404, U.S.A. with Tax ID number 94-3047598 (together with its affiliates and subsidiaries, “Gilead”), in connection with a clinical trial conducted pursuant to Protocol GS- US-296-1080 “A Phase 3 Randomized, Double- Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.” (togeth